Navigation Links
Xoft Introduces Electronic Brachytherapy Cancer Treatment Platform at ESTRO Meeting

BARCELONA, Spain, Sept. 13 /PRNewswire/ -- Xoft, Inc., the pioneer of localized, isotope-free radiation treatment delivered in minimally-shielded clinical settings, today announced the introduction of the Axxent® Electronic Brachytherapy, eBx™ System to physicians and distributors in Europe.  The Axxent eBx System, which delivers treatment directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, treats breast, endometrial and skin cancers and Intraoperative Radiation Therapy (IORT) indications.  The announcement was made here at the 29th Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO), where Xoft is exhibiting for the first time.

Xoft recently received CE Mark Approval for the Axxent Electronic Brachytherapy System and treatment applicators, which permits sales and marketing of the System throughout the European Union. Originally FDA-cleared for the treatment of early stage breast cancer, the Axxent eBx Systems has received supplemental clearances for additional indications and for intraoperative use.  

"With major IORT and other radiation therapy studies having been conducted in Europe over the past several years, the market is primed for launch of Electronic Brachytherapy," said Rob Kirby, Xoft's Vice President of Business Development. "We are excited to formally introduce the Axxent System to European radiation oncologists at ESTRO, and we will also use the meeting to build strong distribution relationships to drive adoption throughout the EU."  

The clinical benefits of isotope-free, 50 kV radiation therapy continue to be substantiated by multiple publications.  The most recent include publication of four-year data from the TARGIT-A (Targeted Intraoperative Radiation Therapy) multicenter clinical trial, and recent Xoft clinical publications on APBI, endometrial cancer and breast IORT.  

As a platform technology, the Axxent System is designed to deliver localized, isotope-free radiation treatment in minimally-shielded clinical settings under the supervision of a radiation oncologist to help reduce recurrence of cancer and improve survival. Utilizing a proprietary miniaturized X-ray source and mobile controller, treatment can be performed without the need for a shielded room, allowing radiation oncologists and medical personnel to be present during treatment, which minimizes patient anxiety.

"With minimal exposure to healthy tissues and rapid dose fall-off that enables treatment in minimally-shielded settings, Electronic Brachytherapy delivers targeted treatment that is professionally validated and patient friendly," said Michael Klein, President and CEO of Xoft.  "Building on years of clinical experience and scientific validation since eBx was first introduced as an X-ray-based, electronic treatment option for early stage breast cancer, we are very pleased to offer this important oncology treatment platform to radiation oncologists and patients in Europe.  Delivering safe, targeted treatment for breast, endometrial, skin and other cancers, we expect eBx will continue to increase access to critical treatment as well as improve compliance and patient care."

About Xoft, Inc.

Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. The Axxent® treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the logistics and costs associated with using radioactive isotopes.  FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer, the Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For information, visit

Axxent is a registered trademark and eBx is a trademark of Xoft, Inc.

SOURCE Xoft, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Open House at Gulf Coast Cancer Treatment Center Introduces Elekta Synergy® to Community
2. Laerdal Introduces SimMan Essential
3. Elsevier Introduces SciVerse, an Innovative Platform for Accelerating Science
4. UPDATE: China PharmaHub Corp. Introduces a Magic Bullet Liver Cancer Therapy to China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, and Bangladesh
5. China PharmaHub Corp. Introduces a Magic Bullet Liver Cancer Therapy to China, Hong Kong, Taiwan, Macau, Singapore, Malaysia, and Bangladesh
6. Medical Website Design Experts Aurora Information Technology Introduces Its Newest Website Launch, Muscat Eye Laser Center
7. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
8. Block Engineering Introduces Family of Quantum Cascade Laser Mid-IR Spectrometers
9. Instrumentation Laboratory Introduces Fully Automated, Liquid, Ready-to-Use HemosIL® HIT-Ab(PF4-H) Assay in Europe
10. Omnicell Introduces New Omnicell Packager With WorkflowRx Software for Improved Pharmacy Efficiency
11. Robotic Surgeon Dr. David Samadi, MD Introduces His SMART Surgery Technique for Prostate Cancer Treatment
Post Your Comments:
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- global cell culture market is expected to ... by 2022 at a CAGR of 7.1% therein. --> ... 2013 value of US$6.1 bn to US$11.3 bn by 2022 at ... has announced the release of a new market research study, detailing ... Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and restoration is ... These techniques and procedures have been in use for many years and are among ... Parsa Mohebi, M.D. has utilized many of these methods over the years, he also ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally ... styling. So why is it a national news story when Donald Trump makes disparaging ... M.D., because appearances count more than anyone wants to admit when it comes to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
Breaking Medicine News(10 mins):